Core Viewpoint - PCI Biotech has decided to discontinue the development of its PCL technology due to insufficient progress towards its 2025 goals, which has raised project risks and extended timelines [2][3]. Operations - The decision to halt PCL development was made on August 18, 2025, primarily due to a lack of convincing results in demonstrating improved net yield at mini benchtop bioreactor scale [2][3]. - Additional initiatives aimed at showcasing PCL's capability to enhance net AAV yield did not yield satisfactory outcomes, leading to increased resource requirements and overall project risk [3]. Corporate - As of June 30, 2025, PCI Biotech's cash position was NOK 13.6 million, which is projected to sustain operations into Q4 2025 [4]. - The company is currently evaluating its future, considering options such as a potential sale, merger, or complete wind-down of operations [4]. - CEO Ronny Skuggedal emphasized that the evaluation process is in its early stages, and no assurances can be provided regarding the outcome [5].